Cancer Research Landon Prizes for Basic and Translational Cancer Research  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 6596-6602, December 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Futami, H.
Right arrow Articles by Wiltrout, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Futami, H.
Right arrow Articles by Wiltrout, R. H.

Flavone Acetic Acid Directly Induces Expression of Cytokine Genes in Mouse Splenic Leukocytes but not in Human Peripheral Blood Leukocytes1

Hitoyasu Futami2, Lou Ann Eader, Kristin L. Komschlies, Robert Bull, M. Eilene Gruys, John R. Ortaldo, Howard A. Young and Robert H. Wiltrout3

Laboratory of Experimental Immunology, Biological Response Modifiers Program, Division of Cancer Treatment [H. F., M. E. G., J. R. O., H. A. Y., R. H. W.], and Biological Carcinogenesis and Development Program, PRI/DynCorp. [L. A. E., K. L. K., R. B.], National Cancer Institute-Frederick Cancer Research and Development Center (NCI-FCRDC), Frederick, Maryland 21702-1201

Flavone-8-acetic acid (FAA) is a flavonoid drug that augments mouse natural killer activity, induces cytokine gene expression, and synergizes with recombinant interleukin 2 for the treatment of murine renal cancer. However, FAA has been largely inactive in human clinical trials. In the present study we investigated the ability of FAA treatment to directly induce cytokine mRNA expression in total mouse splenic leukocytes and selected leukocyte subsets, as well as in total human peripheral blood leukocytes. Analysis of RNA isolated from FAA-treated mouse splenic leukocytes demonstrated that treatment with ≥100 µg/ml of FAA induced expression of tumor necrosis factor {alpha} (TNF-{alpha}) mRNA by 1 h and induced maximal expression of TNF-{alpha}, {alpha}-interferon, and {gamma}-interferon mRNA within 3 h. The expression of all cytokine genes was diminished by 6 h. Interferon biological activity was detected in the supernatants of mouse splenic or peripheral blood leukocytes after treatment with FAA. These results correlate well with the previously reported induction of cytokine mRNA genes and biological activity by FAA in vivo. In contrast, FAA did not induce detectable mRNA expression or cytokine protein secretion by human peripheral blood leukocytes under similar conditions. These results demonstrate that FAA can directly stimulate cytokine gene expression in mouse but not in human leukocytes. Further studies performed with highly purified positively selected mouse CD4+ or CD8+ splenic T-lymphocytes, as well as purified B-cells, demonstrated that the FAA-induced expression of {gamma}-interferon mRNA was mainly induced in the CD8+ lymphocyte subset. {alpha}-Interferon mRNA was expressed largely in the B-cell population, while TNF-{alpha} mRNA was induced in all leukocyte subsets tested. Therefore, these results suggest that the immunomodulatory effects of FAA in mice are direct, but different cytokines are induced from different leukocyte subsets. Further, the data suggest that flavonoid compounds or analogues that stimulate cytokine gene expression in human cells might be therapeutically active in cancer patients.

1 This project has been funded at least in part with federal funds from the Department of Health and Human Services under Contract NO1-CO-74102 with Program Resources, Inc./DynCorp.

2 Recipient of support during the performance of these studies from a Japanese Overseas Cancer Research Fellowship from the Foundation for the Promotion of Cancer Research. Present address: Growth Factor Division, National Cancer Center Research Institute, Tsukiji 5-1-1, Cho-Ku, Tokyo 104, Japan.

3 To whom requests for reprints should be addressed, at the Laboratory of Experimental Immunology, NCI-FCRDC Bldg. 560, Rm. 31-93, Frederick, MD 21702-1201.

Received 7/15/91. Accepted 10/ 3/91.




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. S. Jassar, E. Suzuki, V. Kapoor, J. Sun, M. B. Silverberg, L. Cheung, M. D. Burdick, R. M. Strieter, L.-M. Ching, L. R. Kaiser, et al.
Activation of Tumor-Associated Macrophages by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid Induces an Effective CD8+ T-Cell-Mediated Antitumor Immune Response in Murine Models of Lung Cancer and Mesothelioma
Cancer Res., December 15, 2005; 65(24): 11752 - 11761.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. G. Siim, W. T. Laux, M. D. Rutland, B. N. Palmer, and W. R. Wilson
Scintigraphic Imaging of the Hypoxia Marker 99mTechnetium-labeled 2,2'-(1,4-Diaminobutane)bis(2-methyl-3-butanone) Dioxime (99mTc-labeled HL-91; Prognox): Noninvasive Detection of Tumor Response to the Antivascular Agent 5,6-Dimethylxanthenone-4-acetic Acid
Cancer Res., August 1, 2000; 60(16): 4582 - 4588.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.